The PAI-1 4G/5G polymorphism is not associated with an increased risk of adverse pregnancy outcome in asymptomatic nulliparous women

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 5, 2012, Pages 881-886

  Said, J M ^a,b   Tsui, R ^a,b   Borg, A J ^a   Higgins, J R ^a,b,c   Moses, E K ^a,b,d   Walker, S P ^b,e   Monagle, P T ^b,f,g   Brennecke, S P ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Mercy Hospital for Women   (Germany)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Cohort study; Nulliparous; PAI 1; Pre eclampsia; Pregnancy; Thrombophilia

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; FEMALE; FETUS GROWTH; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NEWBORN DEATH; NULLIPARA; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; SOLUTIO PLACENTAE; STILLBIRTH; THROMBOPHILIA;

ABRUPTIO PLACENTAE; ADULT; ASYMPTOMATIC DISEASES; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; FIBRINOLYSIS; GENETIC PREDISPOSITION TO DISEASE; GESTATIONAL AGE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; ODDS RATIO; PARITY; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STILLBIRTH; VICTORIA;

EID: 84860484918     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04700.x     Document Type: Article

References (21)

1. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol 1995; 173: 1049-57.
2. Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995; 173: 1097-105.
3. Kidron D, Bernheim J, Aviram R. Placental findings contributing to fetal death, a study of 120 stillbirths between 23 and 40weeks gestation. Placenta 2009; 30: 700-4.
4. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7: e1000292.
5. Salame MY, Samani NJ, Masood I, deBono DP. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000; 152: 19-28.
6. Kruithof E, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-6.
7. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120, 000 cases and 180, 000 controls. Thromb Haemost 2009; 102: 360-70.
8. Ye Z, Liu EHC, Higgins JPT, Keavney BD, Lowe GDO, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66, 155 cases and 91, 307 controls. The Lancet 2006; 367: 651-8.
9. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001; 97: 44-8.
10. D'Elia AV, Fabbro D, Driul L, Barillari G, Marchesoni D, Damante G. Plasminogen activator inhibitor-1 gene polymorphisms in pre-eclampsia. Semin Thromb Hemost 2011; 37: 97-105.
11. Wiwanitkit V. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal. Arch Gynecol Obstet 2006; 273: 322-4.
12. Said JM, Higgins JR, Moses EK, Walker SP, Borg AJ, Monagle PT, Brennecke SP. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010; 115: 5-13.
13. Roberts C, Lancaster P. Australian national birthweight percentiles by gestational age. Med J Aust 1999; 170: 114-8.
14. Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, Sharrett AR, Tracy RP. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 2003; 1: 1799-804.
15. de Boer K, Lecander I, ten Cate J, Borm JJ, Treffers PE. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158: 518-22.
16. Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemost 1984; 52: 124-6.
17. Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem 1994; 269: 19095-100.
18. Dimova E, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-10006.
19. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, Tofler GH, Hirschhorn JN, O'Donnell CJ. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005; 112: 1728-35.
20. Franco R, Fagundes M, Meijers J, Reitsma P, Lourenco D, Morelli V, Maffei F, Ferrari I, Piccinato C, Silva W Jr, Zago M. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
21. Uxa R, Baczyk D, Kingdom JCP, Viero S, Casper R, Keating S. Genetic polymorphisms in the fibrinolytic system of placentas with massive perivillous fibrin deposition. Placenta 2010; 31: 499-505.